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Previous analyses suggest children with tuberculosis (TB) are no more or no less likely to have 20 
multidrug- or rifampicin-resistant TB (MDR/RR-TB) than adults. However, the availability of new 21 
data, particularly for high MDR/RR-TB burden countries, suggest updates of country-specific 22 
estimates are warranted.  23 
 24 
We used data from population-representative surveys and surveillance collected between 2000 25 
and 2018 to compare the odds ratio (OR) of MDR/RR-TB among children (<15 years) with TB, 26 
compared to the odds of MDR/RR-TB among adults (≥15 years) with TB.  27 
 28 
In most settings (45/55 countries), and globally as a whole, there is no evidence that age is 29 
associated with odds of MDR/RR-TB. However, in some settings such as former Soviet Union 30 
countries in general, and Georgia, Kazakhstan, Lithuania, Tajikistan and Uzbekistan in particular, 31 
as well as Peru, MDR/RR-TB is positively associated with age ≥15. Meanwhile, in Western Europe 32 
in general, and the UK, Poland, Finland and Luxembourg in particular, MDR/RR-TB is positively 33 
associated with age <15. Sixteen countries had sufficient data to compare over time between 34 
2000-2011 and 2012-2018, with evidence for decreases in the OR in children compared to adults 35 
in Germany, Kazakhstan and the USA. 36 
 37 
Our results support findings that in most settings a child with TB is as likely as an adult with TB to 38 
have MDR/RR-TB. However, setting-specific heterogeneity requires further investigation. Further, 39 
the OR for MDR/RR-TB in children compared to adults is generally either stable or decreasing. 40 
There are important gaps in detection, recording and reporting of drug resistance among 41 
paediatric TB cases, limiting our understanding of transmission risks and measures needed to 42 





MDR, TB, odds ratio, paediatric, child, adult, burden 46 
 47 
Take-home message: Globally, the odds of drug resistance, among those with TB, are the same 48 
for children as for adults. However, setting-specific heterogeneity requires further investigation. 49 





The World Health Organization (WHO) estimated that as many as 484 000 of an estimated 10 53 
million incident tuberculosis (TB) cases had multidrug-resistant (MDR; i.e. Mycobacterium 54 
tuberculosis [M.tb] resistant to both rifampicin and isoniazid) or rifampicin-resistant (RR) TB in 55 
2018. Because mortality and treatment failure rates of those with MDR/RR-TB are significantly 56 
higher than in drug-susceptible TB,[1] and treatment of MDR/RR-TB requires the use of 57 
expensive, toxic drugs over extended periods of time, there is a need to better understand 58 
potential risk factors for MDR/RR-TB and trends in these over time.  59 
 60 
TB disease may occur as a result of rapid progression after infection (within weeks to months), or 61 
many years or even decades after initial infection. Disease in young children must be the result 62 
of infection with more recently circulating M.tb strains. Disease in adults, however, can be the 63 
result of either recent or much older infections. In the case of drug resistance, it is also important 64 
to consider the possibility that the apparent burden of MDR/RR-TB among previously treated 65 
individuals (who are predominantly adults) may reflect either primary transmission of resistant 66 
strains or the emergence of acquired resistance during inadequate treatment. Thus, we would 67 
expect that the risk of MDR/RR-TB among children would be more sensitive than among adults 68 
to changing patterns of drug resistance in the circulating population of M.tb strains.[2] A 69 
systematic review of available data in 2014 [3] showed that the prevalence of MDR/RR-TB among 70 
TB cases in children is the same as the prevalence among treatment-naive adults. We would 71 
expect the prevalence in both of these groups to be a result of transmission of drug-resistant 72 
strains as opposed to emergence of acquired drug-resistance during treatment. Meanwhile, a 73 
previous evaluation (2013) of global surveillance data reached similar conclusions.[4] One area 74 
of concern was the potential for an association between age and MDR-TB in southern African 75 
countries with a high HIV prevalence, although evidence to support this was somewhat limited at 76 
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the time.[4] Since that time, with the introduction and roll-out of the rapid molecular cartridge-77 
based assay, Xpert MTB/RIF, more comprehensive data from a greater number of countries have 78 
become available. However, diagnosing and ensuring access to appropriate treatment for 79 
MDR/RR-TB still remains a challenge, particularly for children,[5] with the vast majority of cases 80 
unlikely to be detected.[2, 6] There is a critical need to better characterize the burden and 81 
transmission risks of MDR/RR-TB in children. 82 
 83 
Here, we reexamine country-level data to assess the burden of MDR/RR-TB in children compared 84 
to adults, including evaluating (where possible) how this has changed over time and what the 85 
implications of this could be. 86 
 87 
METHODS 88 
Data selection 89 
WHO reports annually on aggregated drug resistance surveillance data collected at a national or 90 
a representative subnational level, ensuring data quality and representativeness. The data is 91 
collected through continuous surveillance of drug resistance by routinely conducting drug 92 
susceptibility testing (DST) on the majority of TB patients, or if the coverage of DST is not sufficient 93 
(<80% of bacteriologically confirmed pulmonary TB cases are tested for at least rifampicin 94 
resistance), via periodic drug resistance surveys of a nationally representative sample of patients, 95 
ideally repeated at least every five years.[7] Data for all TB patients (both new and previously 96 
treated patients combined) are captured,  identifying the numbers of individuals in each age group 97 
(children <15 years or adults ≥15 years) that are either resistant or susceptible to isoniazid and 98 
rifampicin. From 2016 onwards, only rifampicin is captured, a change which reflects an increased 99 
use of the Xpert MTB/RIF assay for M.tb diagnosis and DST. Age-disaggregated data is not 100 




We excluded data where the coverage of DST among new bacteriologically confirmed cases was 103 
<80%, where drug resistance was not reported separately for children and adults, or where age-104 
disaggregated drug-resistance data were available, but no paediatric cases of MDR/RR-TB had 105 
been detected. 106 
 107 
Analysis 108 
We calculated the odds ratio (OR) for MDR/RR-TB for children (<15 years old) compared to adults 109 
(≥15 years old) by country, where the OR is given by: 110 
𝑂𝑅 =
𝑜𝑑𝑑𝑠 𝑜𝑓 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵 𝑖𝑛 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 𝑤𝑖𝑡ℎ 𝑇𝐵
𝑜𝑑𝑑𝑠 𝑜𝑓 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵 𝑖𝑛 𝑎𝑑𝑢𝑙𝑡𝑠 𝑤𝑖𝑡ℎ 𝑇𝐵
,  111 
=
(𝑛𝑜𝑡𝑖𝑓𝑖𝑒𝑑 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 𝑤𝑖𝑡ℎ 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵)∗(𝑛𝑜𝑡𝑖𝑓𝑖𝑒𝑑 𝑎𝑑𝑢𝑙𝑡𝑠 𝑤𝑖𝑡ℎ 𝑇𝐵 𝑎𝑛𝑑 𝑎 𝐷𝑆𝑇 𝑟𝑒𝑠𝑢𝑙𝑡 𝑏𝑢𝑡 𝑛𝑜𝑡 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵)
(𝑛𝑜𝑡𝑖𝑓𝑖𝑒𝑑 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 𝑤𝑖𝑡ℎ 𝑇𝐵 𝑎𝑛𝑑 𝑎 𝐷𝑆𝑇 𝑟𝑒𝑠𝑢𝑙𝑡 𝑏𝑢𝑡 𝑛𝑜𝑡 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵)∗(𝑛𝑜𝑡𝑖𝑓𝑖𝑒𝑑 𝑎𝑑𝑢𝑙𝑡𝑠 𝑤𝑖𝑡ℎ 𝑀𝐷𝑅/𝑅𝑅−𝑇𝐵)
. 112 
We calculated 95% confidence intervals (95% CI) using the standard error of the log odds ratio. 113 
We used a random-effects meta-analysis in the meta package in R[8] to analyse available data 114 
across WHO regions, dividing the European Region into the Former Soviet Union and Western 115 
Europe, given that the percentage of new and previously treated TB cases with MDR/RR-TB in 116 
these two regions is markedly different[1] due to historic treatment and health system approaches. 117 
 118 
Temporal change 119 
We calculated the OR for the periods 2000-2011 and 2012-2018. This represents recent data 120 
compared to when the OR for MDR/RR-TB in children compared to adults in surveillance data 121 
was last evaluated by Zignol and Colleagues,[4] since which time Xpert MTB/RIF testing has also 122 
been introduced. To establish evidence for a trend, we used a likelihood ratio test to assess for 123 
an interaction between age group and year at various levels of confidence, noting strong evidence 124 
for a change in OR (99% confidence), evidence (95%), weak evidence (90%) and very weak 125 




A changing OR can be interpreted in different ways, implying different combinations of increasing 128 
or decreasing drug-susceptible and MDR/RR-M.tb transmission, which we outline in Table 1 – 129 
building on previously established concepts.[9] We show in the appendix that the link between 130 
changes in the OR and recent transmission of MDR/RR-TB are not necessarily intuitive.  131 
 132 
RESULTS 133 
Selection of countries 134 
Of the 212 countries and territories reporting TB data to WHO, 71 did not have any high quality 135 
MDR/RR-TB data from 2000-2018. Of the remaining 141 countries with good quality data, 86 had 136 
age-disaggregated data but reported no paediatric MDR/RR-TB cases, suggesting potential 137 
sample sizes limitations in some of the 31 of these that relied on survey data. This left 55 countries 138 
with good quality age-disaggregated data for MDR/RR-TB (Figure 1). 139 
 140 
When comparing data over the two different time periods, 39/55 countries had either age-141 
disaggregated data available for one period and not the other, and/or paediatric MDR/RR-TB 142 
cases reported in one period and not the other. Nineteen of these countries relied on periodic 143 
surveys.  144 
 145 
In total, 16 countries recorded paediatric MDR/RR-TB cases in both 2000-2011 and 2012-2018; 146 
Austria, Belarus, Belgium, Germany, Kazakhstan, Latvia, Namibia, Netherlands, Poland, 147 
Republic of Moldova, Spain, Sweden, Switzerland, the United Kingdom, the United States of 148 
America and Uzbekistan. In all except Namibia and Uzbekistan, where surveys were conducted, 149 
these data were derived from continuous surveillance. 150 
  151 
Odds ratio 152 
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Aggregated ORs by country are shown in Table 2, where there were a total of 9 922 DST results 153 
for children and 605 089 for adults. Of the 55 included countries, there is strong evidence of ORs 154 
less than 1 (MDR/RR-TB is positively associated with age ≥15 years) in Georgia, Kazakhstan, 155 
Lithuania, Peru, Tajikistan, and Uzbekistan, and of ORs greater than 1 (MDR/RR-TB is positively 156 
associated with age <15 years) in the United Kingdom and Poland. There is also weak evidence 157 
of ORs greater than 1 in Finland and Luxembourg. 158 
 159 
A forest plot of the OR by WHO region is shown in Figure 2, where we split the WHO European 160 
Region into a Former Soviet Union region (which included Armenia, Azerbaijan, Belarus, Estonia, 161 
Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, 162 
Ukraine and Uzbekistan) and a Western Europe region (all other countries from the WHO 163 
European Region). There was strong evidence for an OR less than  1 in the Former Soviet Union 164 
at 0.50 [95% CI 0·41-0·60], and evidence in for an OR greater than 1 in the Western Europe 165 
region at 1.34 [95% CI 1.06-1.70]. There was weak evidence for an OR greater than 1 in the WHO 166 
Western Pacific Region at 1.76 [95% CI 1.00-3.09], and very weak evidence in the African Region 167 
at 1.37 [95% CI 0.89-2.11]. Globally, there was no evidence for an OR significantly different to 1, 168 
at 1.11 [95% CI 0.92-1.33]. 169 
 170 
Of the 16 countries with data for both 2000-2011 (when there were 3564 DST results for children 171 
and 166 726 for adults in the 16 countries considered here) and 2012-2018 (2460 DST results for 172 
children and 159 150 for adults) in the majority (n=9) confidence intervals were too wide to show 173 
evidence of a changing OR over time (Figure 3, see appendix for further details). We found strong 174 
evidence for decreases in the OR of MDR/RR-TB in children compared with adults between 2000-175 
2011 and 2012-2018 in three countries: Germany (1·64[95% CI 1·12-2·39] in 2000-2011, 176 
decreasing to 0·26[95% CI 0·07-1·07] in 2012-2018), Kazakhstan (1·03[95% CI 0·71-1·5] to 177 
0·38[95% CI 0·31-0·45]) and the USA (2·35[95% CI 1·45-3·80] to 0·63[95% CI 0·28-1·42]). We 178 
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found weak evidence for an increasing OR in Belgium (significant at a 90% level of confidence), 179 
and very weak evidence for a declining OR in Belarus, Namibia and Uzbekistan (significant at an 180 
85% level of confidence), with no evidence for a changing OR in the remaining nine countries. In 181 
a random-effects meta-analysis with all included countries, the mean OR decreased from 1·39 182 
[95% CI 1·05-1·84] in the 2000-2011 period to 0·72 [95% CI 0·49-1·06] in the 2012-2018 period. 183 
 184 
In an analysis of the WHO European Region, we divided this as described above into Western 185 
Europe (comprised here of Austria, Belgium, Germany, Netherlands, Poland, Spain, Sweden, 186 
Switzerland and the United Kingdom) and the Former Soviet Union (comprised of Belarus, 187 
Kazakhstan, Latvia, Republic of Moldova and Uzbekistan). We found no evidence for a changing 188 
OR in Western Europe (1·63 [95% CI 1·27-2·10] compared to 1·18 [95% CI 0·68-2·07]). However, 189 
there was evidence for a decreasing OR in the Former Soviet Union (0·95 [95% CI 0·72-1·26] to 190 
0·43 [95% CI 0·31-0·60]), although this was no longer the case if data from Kazakhstan was 191 
removed (0·85 [95% CI 0·54-1·35] to 0·48 [95% CI 0·27-0·84]). 192 
 193 
DISCUSSION 194 
In most settings (45/55 countries with high quality data and reporting paediatric cases of MDR/RR-195 
TB), and globally as a whole, there is no evidence that age is associated with odds of MDR/RR-196 
TB. However, in some settings such as the Former Soviet Union countries in general, and 197 
Georgia, Kazakhstan, Lithuania, Tajikistan and Uzbekistan in particular, as well as Peru, 198 
MDR/RR-TB is positively associated with age ≥15 years. Meanwhile, in the rest of Europe in 199 
general, and the United Kingdom, Poland, Finland and Luxembourg in particular, MDR/RR-TB is 200 
positively associated with age <15 years. There is also weak evidence that MDR/RR-TB is 201 
positively associated with age <15 years in the Western Pacific and African regions, which 202 




Sixteen countries, primarily located in the WHO European Region, had sufficient data to compare 205 
the change over time between 2000-2011 and 2012-2018. We found strong evidence for 206 
decreases in the OR of MDR/RR-TB in children compared to adults in Germany, Kazakhstan and 207 
the USA, and very weak evidence for a decline in Belarus, Namibia and Uzbekistan. At the same 208 
time, total TB incidence was decreasing, suggesting that transmission of drug-susceptible TB was 209 
decreasing (see appendix and scenario 3 in table 1). This may mean that MDR/RR-TB 210 
transmission may have been decreasing over time in those settings (see appendix for further 211 
details), although we note that the low number of children with MDR/RR-TB in particular means 212 
that it is difficult to draw broad conclusions about changes in transmission. Weak evidence for an 213 
increasing OR in Belgium is unfortunately difficult to interpret and could reflect either an increase 214 
or decrease in MDR/RR-TB transmission (scenarios 4 or 6 in table 1). As a caveat, we note that 215 
in countries where a large fraction (often the majority) of TB occurs among foreign-born 216 
individuals, the interpretation of the OR as a measure of the relative risk of local transmission of 217 
MDR/RR-M.tb versus drug-susceptible M.tb is likely not valid. In Germany, the USA and Belgium 218 
in particular, low rates of local transmission[10] mean that changes in the OR reflect changes that 219 
are happening outside the country.  220 
 221 
In general agreement with previous research,[3, 4] we find that in the majority of settings, there is 222 
no evidence that the odds of MDR/RR-TB for children are likely to be different to adults. The 223 
inclusion of data from an additional 20 countries, including 7 high MDR/RR-TB burden countries 224 
not previously considered, totaling an additional 3 852 (63%) children and 288 113 (91%) adults, 225 
strengthens these findings. We also find some very weak evidence to support previous concerns 226 
over the odds for children in southern African countries with a high HIV burden such as Namibia, 227 
Lesotho and Eswatini, although data for these countries remains limited and it is difficult to draw 228 
broad conclusions. Indeed, only in Western Europe, a setting with very low numbers of MDR/RR-229 
TB cases,[1] is there evidence of worse odds for children than adults, in line with previous findings 230 
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from >5 years ago.[4] We do find that the odds for children compared to adults may be setting-231 
specific, with evidence that children have much lower odds of MDR/RR-TB in countries of the 232 
Former Soviet Union (where higher quality data are more widely available), an aspect that had 233 
not previously been identified. As such, previous calculations[3, 6, 11] of the number of children 234 
with MDR/RR-TB in these high MDR/RR-TB burden settings may have been overestimated. In 235 
addition, several settings, particularly Western Europe but also the Western Pacific and Africa 236 
Regions, require further investigation to identify if children do indeed have higher odds of 237 




However, we note that interpretation of our results is based on the implicit assumption that the 242 
odds ratio calculated reflects the ratio of actual MDR/RR-TB burden in children compared to 243 
adults. In reality, our results are only for the subset of cases for whom DST results are available, 244 
which is particularly challenging in children.[2] If the case detection ratio for MDR/RR-TB 245 
compared to DS-TB is different for adults than children then the odds we calculate could be biased 246 
upward or downward. Examples of such biases include rigorousness of DST testing for children 247 
(who are less likely to obtain bacteriological confirmation than adults), particularly if this increases 248 
for household contacts of MDR/RR-TB cases, and systematic screening in adult populations with 249 
a high MDR/RR-TB prevalence such as prison populations in the former Soviet Union. The latter 250 
could in fact explain the high odds of MDR/RR-TB in adults in the former Soviet Union. The 251 
available data do not allow us to determine the magnitude of these detection biases in our 252 
analysis. 253 
 254 
Beyond the biases mentioned above, in some settings such as the former Soviet Union clustering 255 
of MDR/RR-TB cases in certain settings composed of adults,  notably prisons,[12] could explain 256 
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why adults have higher odds of MDR/RR-TB. Meanwhile, high odds of MDR/RR-TB for children 257 
in Western Europe, where DST rates are high,[1] could represent an association that data 258 
elsewhere is not representative enough to identify. Potentially high odds of MDR/RR-TB for 259 
children in the Western Pacific and African regions are worrying, where the latter and its potential 260 
interaction with HIV has been previously identified as a concern.[4] However, the evidence from 261 
our results here is weak, and requires further investigation. 262 
 263 
Where there is data to compare any change over time, in many cases the odds for children 264 
compared to adults are either unchanged or improving. Given the potential importance of children 265 
as sentinels for TB transmission,[2] this is in line with a comparatively stable MDR/RR-TB 266 
incidence globally,[1] although more evidence is required before conclusions can be drawn. 267 
Indeed, we note that this lack of statistical significance for country-specific odds is not necessarily 268 
an indication of a similar force of infection for children and adults, but may reflect limitations in 269 
available data, particularly the low number of recorded children with MDR/RR-TB. 270 
 271 
As mentioned above, differences in case detection remain a further limitation of our study; namely, 272 
changes in the TB diagnostic algorithm over time may have been implemented differently among 273 
children compared to adults. In particular, the adoption of Xpert MTB/RIF as the initial diagnostic 274 
test in place of smear microscopy may have been more common in children, due to resource 275 
limitations in some settings preventing testing of all patient groups. The available data do not 276 
allow an assessment of how the proportion of bacteriologically confirmed cases for which DST 277 
was performed has changed over time for children compared to adults. At the same time, as in 278 
work by Zignol et al [4], we were not able to separate treatment naive from previously treated 279 
cases in our data, where, as previously noted, the latter are more likely to be adults. In 280 
comparison, Jenkins et al [3] compare children to treatment naïve adults only, finding no 281 
difference. In our results, in addition to both previous instances, there is no evidence for a 282 
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difference in odds by age, suggesting that either the importance of resistance acquisition in adults 283 
due to previous treatment is limited, or, more likely, that additional evidence is required to better 284 
understand the odds. 285 
 286 
Finally, our analysis included data from only 13 of the 30 high MDR/RR-TB burden countries 287 
defined by WHO for the period of 2016-2020, and only four had data available for both time 288 
periods examined; namely, Belarus, Kazakhstan, Republic of Moldova and Uzbekistan. Half of 289 
the world’s estimated incident RR-TB cases in 2018 were found in India, China and Russian 290 
Federation, yet only limited high quality data were available; indeed, in each country there was 291 
only one year where any paediatric MDR/RR-TB cases were reported. These gaps highlight the 292 
urgent need to strengthen diagnostic capacity through expanded sample referral systems and 293 
laboratory networks. Countries should strive towards achieving universal DST for all people with 294 
TB, as called for in WHO’s End TB Strategy [13]. This should be coupled with the establishment 295 
of electronic case-based surveillance systems which would allow for finer age disaggregation than 296 
the cut-off of 15 years of age that we use here, allowing for comparisons in risk between groups 297 
such as younger children, adolescents and older adults. Without these advances in diagnosis, 298 
recording and reporting of cases in children, we cannot fully understand the burden and 299 
transmission risks of MDR/RR-TB in children, or trends in these over time.  300 
 301 
CONCLUSION 302 
Our results support previous findings that, in most settings, there is no evidence for a difference 303 
in odds of MDR/RR-TB for children compared to adults; a child with TB is as likely as an adult 304 
with TB to have MDR/RR-TB. However, there is evidence of setting-specific heterogeneity in the 305 
Former Soviet Union and Western Europe, as well as weak evidence in the Western Pacific and 306 
African Regions. For the small number of countries where sufficient data are available, the OR 307 
for MDR/RR-TB in children compared to adults is generally either stable or decreasing, which is 308 
14 
 
in line with the stable incidence of MDR/RR-TB at the global level. This analysis highlights 309 
important gaps in the detection, recording and reporting of drug resistance among paediatric TB 310 
cases, limiting our understanding of transmission risks and measures needed to combat the 311 
global TB epidemic.  312 
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FIGURES AND TABLES 372 
Figure 1: Countries with WHO-reported drug resistance survey/surveillance data for 2000–2018 373 
disaggregated by age (children <15 years or adults ≥15 years), showing evidence for the odds 374 
ratio for MDR/RR-TB in children versus adults being different to 1; i.e. an association between 375 
age and MDR/RR-TB.  376 
 377 
Figure 2:  Forest plot showing odds ratios and 95% confidence interval for MDR/RR-TB in children 378 
(<15 years) versus adults (≥15 years) by WHO region (Region of the Americas AMR, African 379 
Region AFR, Eastern Mediterranean Region EMR, South-East Asia Region SEA, Western Pacific 380 
Region WPR, with the European Region separated into the Former Soviet Union FSU and 381 
Western Europe WER). Data among all (new and retreated) cases are presented. 382 
 383 
Figure 3: Trends over time in odds ratios for MDR/RR-TB in children (<15 years) versus adults 384 
(≥15 years) using 95% confidence intervals. Countries (indicated by iso3 code) are (a) Austria, 385 
(b) Belarus, (c) Belgium, (d) Germany, (e) Kazakhstan, (f) Latvia, (g) Namibia, (h) Netherlands, 386 
(i) Poland, (j) Republic of Moldova, (k) Spain, (l) Sweden, (m) Switzerland, (n) United Kingdom, 387 
(o) United States of America and (p) Uzbekistan. 388 
 389 
Table 1: Potential scenarios indicated by changes in the odds ratio (OR) in children vs. adults. 390 
These include whether transmission is increasing or decreasing for DS-TB and MDR/RR-TB, and 391 
how the magnitude in this change compares for DS-TB vs. MDR/RR-TB. Arrows indicate whether 392 
transmission is increasing (↑) or decreasing (↓), where multiple arrows indicate a greater change 393 
in transmission is likely (but not guaranteed) to have taken place. See appendix for further details. 394 




OR decrease (↓) Scenario 1 ↑ ↓ 
Scenario 2 ↑↑ ↑ 
Scenario 3 ↓ ↓↓ 
OR increase (↑) Scenario 4 ↓ ↑ 
Scenario 5 ↑ ↑↑ 
Scenario 6 ↓↓ ↓ 
 395 
Table 2: Countries with at least 1 paediatric MDR- (pre-2016) or MDR/RR-TB (post-2016) case, 396 
identifying years with age disaggregation with and without paediatric cases. Countries in bold 397 
have a 95% confidence interval (CI) for the odds ratio for MDR/RR-TB for children (<15 years old) 398 
compared to adults (≥15 years old) not overlapping 1. 399 








Number of cases tested 
(and identified in [ ]) for 
isoniazid and rifampicin* 
resistance 
Pooled odds 







Argentina 2005  17 [1] 793 [35] 1·35 (0·17-10·5) 














227 [5] 7 151 [177] 0·89 (0·36-2·18) 
Azerbaijan 2007  11[3] 1 090[428] 0·58 (0·15-2·20) 
Bangladesh 2011  13[1] 1 331[98] 1·05 (0·13-8·15) 
Belarus 2011, 
2014-2017 










353 [7] 9 068 [185] 0·97 (0·45-2·08) 
Bhutan 2017  3 [1] 382 [52] 3·17 (0·28-35·62) 
Burkina Faso 2017  9 [1] 1 131 [40] 3·41 (0·42-27·92) 
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Chile 2015 2014, 2017 66 [1] 4 410[77] 0·87 (0·12-6·32) 
China 2013 2002, 2004, 
2005 
47 [2] 12 509 [951] 0·54 (0·13-2·23) 





145 [1] 3 332 [23] 1·00 (0·13-7·45) 
Djibouti 2015  11 [1] 355 [32] 1·01 (0·13-8·14) 


























Hong Kong 2017 2005, 2007, 
2008, 2011 
93 [1] 14 614 [124] 1·27 (0·18-9·19) 
India 2006 2004 36[1] 2 799[220] 0·33 (0·05-2·46) 





51 [1] 2 892 [35] 1·63 (0·22-12·15) 
Israel 2013 2008, 2011, 
2012, 2014- 
2017 
31 [1] 1 568 [86] 0·57 (0·08-4·26) 




 663 [201] 43 401 [20 
735] 
0·48 (0·40-0·56) 




















64 [5] 17 371 [3 
474] 
0·34 (0·14-0·85) 
Luxembourg 2011 2000- 2006, 
2012, 2014 
9 [1] 310 [4] 9·56 (0·96-95·48) 
Namibia 2008, 
2015 
 92 [7] 4 340 [227] 1·49 (0·68-3·26) 








228 [3] 9 727 [133] 0·96 (0·30-3·04) 











121 [3] 3 198 [65] 1·23 (0·38-3·96) 
Pakistan 2013  37 [1] 1 513 [91] 0·43 (0·06-3·20) 
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159 [2] 15 932 [312] 0·64 (0·16-2·58) 










 47 [14] 13 408 [5 
350] 
0·64 (0·34-1·20) 





2004 2003, 2005, 
2006 
5 [1] 2 733 [532] 1·03 (0·12-9·27) 
Saudi Arabia 2010  82 [2] 1 822 [74] 0·59 (0·14-2·45) 





2003-2005 101 [2] 3 515 [85] 0·82 (0·20-3·36) 

















126 [2] 5 285 [99] 0·84 (0·21-3·46) 
Tajikistan 2014, 
2017 




2011, 2014 363 [14] 27 121 [1 
217] 
0·85 (0·50-1·46) 






1 193 [27] 56 905 [664] 1·96 (1·33-2·89) 








2005 204 [23] 7 643 [2 287] 0·30 (0·19-0·46) 
Vanuatu 2017  1 [1] 45 [0] - 
Yemen 2011  22 [1] 1 215 [31] 1·82 (0·24-13·95) 
*rifampicin only for 2016-2018. 400 
 401 
